This article was originally published in The Gray Sheet
Stockholder and underwriter of previous American BioMed offering Robert Todd Financial Corp. files statement with the Securities and Exchange Commission in connection with the sale of 100,000 shares of the catheter manufacturer's stock. The company will not receive any proceeds from the sale of the stock, which may be offered "from time to time" by the seller. The prospectus notes that the firm is currently conducting limited human trials of its 8 French OmniCath atherectomy catheter for peripheral use and is developing 3.8 and 4.5 French versions of the device for use in coronary arteries. The firm is also developing several versions of its Evert-O- Cath toposcopic catheter for coronary and non-coronary therapeutic uses. A preliminary version of the Evert-O-Cath has been approved for non-coronary diagnostic applications; the company currently is awaiting 510(k) clearance for modifications that were made to the device. The firm also is in preliminary stages of development of cardiac assist devices....
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.